Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in Net LoansChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Gains from Investment Securities (2018 - 2025)

Abvc Biopharma (ABVC) has disclosed Gains from Investment Securities for 8 consecutive years, with $258710.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Investment Securities rose 123.34% year-over-year to $258710.0, compared with a TTM value of $258710.0 through Dec 2025, up 128.61%, and an annual FY2025 reading of $258710.0, up 148.56% over the prior year.
  • Gains from Investment Securities was $258710.0 for Q4 2025 at Abvc Biopharma, up from -$1.1 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $1.3 million in Q4 2021 and bottomed at -$1.5 million in Q3 2023.
  • Average Gains from Investment Securities over 5 years is $4394.6, with a median of $36979.0 recorded in 2023.
  • The sharpest move saw Gains from Investment Securities surged 11985.38% in 2021, then crashed 12350.88% in 2023.
  • Year by year, Gains from Investment Securities stood at $1.3 million in 2021, then tumbled by 100.14% to -$1786.0 in 2022, then skyrocketed by 10072.96% to $178117.0 in 2023, then plummeted by 722.2% to -$1.1 million in 2024, then surged by 123.34% to $258710.0 in 2025.
  • Business Quant data shows Gains from Investment Securities for ABVC at $258710.0 in Q4 2025, -$1.1 million in Q4 2024, and $258710.0 in Q3 2024.